NCT03895996: A trial that was reported late by Avotres Inc.
This trial has reported, although it was 421 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03895996 |
|---|---|
| Title | A Phase 1 / 2 Double-Blind, Randomized, Placebo Controlled Study of Safety, Tolerability and Potential Efficacy of AVOTRES Cell-Based Therapy (AVT001) in Patients With Type 1 Diabetes |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 20, 2019 |
| Completion date | May 17, 2022 |
| Required reporting date | May 17, 2023, midnight |
| Actual reporting date | July 11, 2024 |
| Date last checked at ClinicalTrials.gov | Oct. 27, 2025 |
| Days late | 421 |